Commercial Officer, will provide an overview of our limited commercial launch. We'll then provide updates on our major growth initiatives, the on-demand 12-lead patch, and our heart attack detection and AI efforts, followed by the financial results. We'll end with Q&A. I'll bri

May 13, 2026 / receipt

EXPAND COMMERCIAL TEAM

ir_statement / Sep 17, 2026 / receipt

FURTHER EXPAND TEAM

ir_statement / Sep 17, 2026 / receipt

19% decrease compared to same quarter prior year.

ir_statement / Sep 17, 2026 / receipt

Continued judicious timing of investments providing ability to maintain low cost profile.

ir_statement / Sep 17, 2026 / receipt

Operating cash outflow expected to be below $16.0M in 2026, reduced from the $17.0M-$19.0M range previously guided to.

ir_statement / Sep 17, 2026 / receipt

Built flagship account presence in New York, Dallas, South Florida and Southern California

ir_statement / Sep 17, 2026 / receipt

Capital-efficient strategy; judicious timing of investments

ir_statement / Sep 17, 2026 / receipt

Cost-effective expansion strategy does not require large sales force

ir_statement / Sep 17, 2026 / receipt

Expand sales team for regional growth

ir_statement / Sep 17, 2026 / receipt

SCALING EFFICIENTLY WITHOUT THE NEED FOR A LARGE FIELD FORCE

ir_statement / Sep 17, 2026 / receipt

Built flagship account presence in New York, Dallas, South Florida and Southern California

ir_statement / Sep 17, 2026 / receipt

Demonstrating ability to access large patient populations through a focused set of strategically selected practices, with a very lean commercial team

ir_statement / Sep 17, 2026 / receipt